Francesc ViÃ±als

List of Publications by Year
in descending order

60 papers	5,608 citations	126907 33 h-index	128289 60 g-index
61 all docs	61 docs citations	61 times ranked	9468 citing authors

#	Article	IF	Citations
1	Rethinking growth factors: the case of BMP9 during vessel maturation. Vascular Biology (Bristol,) Tj ETQq1 1 0.784314 rgBT /Overloc	3.2	5
2	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. EMBO Molecular Medicine, 2021, 13, e13929.	6.9	6
3	Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M. Biomedicine and Pharmacotherapy, 2020, 121, 109601.	5.6	9
4	SGK1 is a signalling hub that controls protein synthesis and proliferation in endothelial cells. FEBS Letters, 2020, 594, 3200-3215.	2.8	14
5	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with <scp>PARP</scp> inhibitors. EMBO Molecular Medicine, 2020, 12, e11217.	6.9	37
6	PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1. Cells, 2019, 8, 971.	4.1	38
7	PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. Oncogene, 2019, 38, 5021-5037.	5.9	26
8	Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. Clinical Cancer Research, 2018, 24, 3755-3766.	7.0	17
9	ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1216-1229.	2.4	75
10	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. Molecular Cancer Therapeutics, 2018, 17, 532-543.	4.1	28
11	Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility. Nature Communications, 2018, 9, 4826.	12.8	53
12	TGFÎ² Controls Ovarian Cancer Cell Proliferation. International Journal of Molecular Sciences, 2017, 18, 1658.	4.1	26
13	The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget, 2016, 7, 48265-48279.	1.8	10
14	The TGFÎ² pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. International Journal of Cancer, 2016, 139, 1894-1903.	5.1	53
15	Therapeutic Benefit of Selective Inhibition of p110Î± PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	7.0	35
16	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Reports, 2016, 15, 1134-1143.	6.4	96
17	Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression. Cancer Research, 2016, 76, 1245-1259.	0.9	21
18	Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. BMC Cancer, 2015, 15, 59.	2.6	20

#	Article	IF	Citations
19	PTEN mediates Notch-dependent stalk cell arrest in angiogenesis. Nature Communications, 2015, 6, 7935.	12.8	86
20	A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nature Communications, 2014, 5, 3608.	12.8	94
21	Mitochondrial Phosphoenolpyruvate Carboxykinase (PEPCK-M) Is a Pro-survival, Endoplasmic Reticulum (ER) Stress Response Gene Involved in Tumor Cell Adaptation to Nutrient Availability. Journal of Biological Chemistry, 2014, 289, 22090-22102.	3.4	148
22	The impact of KRAS mutations on VEGF-A production and tumour vascular network. BMC Cancer, 2013, 13, 125.	2.6	25
23	Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. BMC Cancer, 2013, 13, 382.	2.6	21
24	<scp>CDK</scp>â€mediated activation of the <scp>SCF^{FBXO}</scp>²⁸ ubiquitin ligase promotes <scp>MYC</scp>â€driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Molecular Medicine, 2013, 5, 1067-1086.	6.9	61
25	Metronomic chemotherapy following the maximum tolerated dose is an effective antiâ€tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. International Journal of Cancer, 2013, 133, 2464-2472.	5.1	76
26	Inhibition of the p110Î± isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. Journal of Experimental Medicine, 2013, 210, 1937-1945.	8.5	56
27	Sertoli-secreted FGF-2 induces PFKFB4 isozyme expression in mouse spermatogenic cells by activation of the MEK/ERK/CREB pathway. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E695-E707.	3.5	16
28	RANK Induces Epithelialâ€“Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis. Cancer Research, 2012, 72, 2879-2888.	0.9	172
29	Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer. Clinical Cancer Research, 2012, 18, 5399-5411.	7.0	86
30	Filamin B Plays a Key Role in Vascular Endothelial Growth Factor-induced Endothelial Cell Motility through Its Interaction with Rac-1 and Vav-2. Journal of Biological Chemistry, 2010, 285, 10748-10760.	3.4	75
31	Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. Clinical Cancer Research, 2009, 15, 3384-3395.	7.0	57
32	Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell, 2009, 15, 220-231.	16.8	2,168
33	Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. Clinical and Translational Oncology, 2009, 11, 780-786.	2.4	27
34	BMPâ€2 regulation of PTHrP and osteoclastogenic factors during osteoblast differentiation of C2C12 cells. Journal of Cellular Physiology, 2008, 216, 144-152.	4.1	29
35	Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Molecular Cancer Therapeutics, 2008, 7, 638-647.	4.1	61
36	Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3Î² activity in human breast cancer cells. Molecular Cancer Therapeutics, 2007, 6, 362-369.	4.1	60

#	Article	IF	Citations
37	The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochemical Pharmacology, 2007, 74, 1340-1349.	4.4	43
38	Molecular mechanisms involved in the adenosine A1 and A2A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. Journal of Neurochemistry, 2005, 92, 337-348.	3.9	56
39	Myogenin Protein Stability Is Decreased by BMP-2 through a Mechanism Implicating Id1. Journal of Biological Chemistry, 2004, 279, 45766-45772.	3.4	40
40	BMP-2 decreases Mash1 stability by increasing Id1 expression. EMBO Journal, 2004, 23, 3527-3537.	7.8	97
41	Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick?s disease. Acta Neuropathologica, 2004, 107, 185-189.	7.7	30
42	cAMP inhibits TGFÎ²1-induced in vitro angiogenesis. FEBS Letters, 2004, 569, 105-111.	2.8	19
43	Identification of a novel proliferation-dependent C-rich element that mediates inhibition of the rat GLUT1 promoter. Gene, 2003, 322, 47-55.	2.2	3
44	Regulation of ubiquitous 6-phosphofructo-2-kinase by the ubiquitin-proteasome proteolytic pathway during myogenic C2C12 cell differentiation. FEBS Letters, 2003, 550, 23-29.	2.8	30
45	Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMPâ€2. FEBS Letters, 2002, 510, 99-104.	2.8	118
46	MPP+ increases Î±-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Research, 2002, 935, 32-39.	2.2	132
47	Growth factor-stimulated protein synthesis is inhibited by sodium orthovanadate. FEBS Journal, 2001, 268, 2308-2314.	0.2	9
48	Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochemical Pharmacology, 2000, 60, 1171-1178.	4.4	184
49	Signaling Angiogenesis via p42/p44 MAP Kinase Cascade. Annals of the New York Academy of Sciences, 2000, 902, 187-200.	3.8	119
50	Factors Involved in GLUT-1 Glucose Transporter Gene Transcription in Cardiac Muscle. Journal of Biological Chemistry, 1999, 274, 17626-17634.	3.4	49
51	p70 S6 Kinase-mediated Protein Synthesis Is a Critical Step for Vascular Endothelial Cell Proliferation. Journal of Biological Chemistry, 1999, 274, 26776-26782.	3.4	143
52	High glucose concentrations inhibit glucose phosphorylation, but not glucose transport, in human endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1450, 119-129.	4.1	16
53	GLUT1 glucose transporter gene transcription is repressed by Sp3. Evidence for a regulatory role of Sp3 during myogenesis 1 1Edited by M. Yaniv. Journal of Molecular Biology, 1999, 294, 103-119.	4.2	53
54	p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts. Journal of Biological Chemistry, 1998, 273, 18165-18172.	3.4	272

#	Article	IF	Citations
55	Myogenesis and MyoD Down-regulate Sp1. Journal of Biological Chemistry, 1997, 272, 12913-12921.	3.4	64
56	Effect of cations on the tyrosine kinase activity of the insulin receptor: inhibition by fluoride is magnesium dependent. Molecular and Cellular Biochemistry, 1997, 171, 69-73.	3.1	14
57	Phosphatidylinositol 3-Kinase Inhibitors Block Differentiation of Skeletal Muscle Cells. Journal of Biological Chemistry, 1996, 271, 19146-19151.	3.4	194
58	Regulation of System A amino-acid transport activity by phospholipase C and cAMP-inducing agents in skeletal muscle. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1176, 155-161.	4.1	6
59	System A transport activity is stimulated in skeletal muscle in response to diabetes. FEBS Letters, 1992, 310, 51-54.	2.8	28
60	Identification and regulation of the endothelial glucose transporter by glucose and insulin. Journal of Molecular and Cellular Cardiology, 1992, 24, S107.	1.9	0